Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

RedHill Biopharma (RDHL) Research & Development (2016 - 2023)

RedHill Biopharma has reported Research & Development over the past 12 years, most recently at $1.2 million for Q2 2023.

  • Quarterly Research & Development fell 15.29% to $1.2 million in Q2 2023 from the year-ago period, while the trailing twelve-month figure was $5.1 million through Jun 2023, down 68.71% year-over-year, with the annual reading at $2.0 million for FY2025, 27.39% up from the prior year.
  • Research & Development was $1.2 million for Q2 2023 at RedHill Biopharma, up from $1.1 million in the prior quarter.
  • Over five years, Research & Development peaked at $10.3 million in Q2 2021 and troughed at $1.1 million in Q1 2023.
  • The 5-year median for Research & Development is $3.1 million (2020), against an average of $4.1 million.
  • Year-over-year, Research & Development soared 221.34% in 2021 and then plummeted 85.75% in 2022.
  • A 5-year view of Research & Development shows it stood at $2.3 million in 2019, then soared by 171.92% to $6.2 million in 2020, then fell by 5.19% to $5.9 million in 2021, then crashed by 80.69% to $1.1 million in 2022, then rose by 10.06% to $1.2 million in 2023.
  • Per Business Quant, the three most recent readings for RDHL's Research & Development are $1.2 million (Q2 2023), $1.1 million (Q1 2023), and $1.1 million (Q4 2022).